Release Notes

Release Notes

Type: Enhancement

Title: Update to Covid vaccinations for the Autumn Winter Campaign 2024

Explanation:

• Addition of New Covid Vaccines
  • Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna, Inc)
  • Comirnaty JN.1 COVID-19 mRNA Vaccine 30micrograms/0.3ml dose dispersion for injection multidose vials (Pfizer Ltd)
  • Comirnaty JN.1 Children 5-11 years COVID-19 mRNA Vaccine 10micrograms/0.3ml dose dispersion for injection single dose vials (Pfizer Ltd)
  • Comirnaty JN.1 Children 6 months – 4 years COVID-19 mRNA Vaccine 3micrograms/0.3ml dose concentrate for dispersion for injection multidose vials (Pfizer Ltd)
• Decommisioning of Previous Covid Vaccines
  • Comirnaty Original/Omicron BA.4-5 COVID-19 mRNA Vaccine 15micrograms/15micrograms/0.3ml dose dispersion for injection multidose vials (Pfizer Ltd)
  • Spikevax XBB.1.5 COVID-19 mRNA Vaccine 0.1mg/1ml dispersion for injection multidose vials (Moderna, Inc)
  • Comirnaty Omicron XBB.1.5 COVID-19 mRNA Vaccine 30micrograms/0.3ml dose dispersion for injection multidose vials (Pfizer Ltd)
  • Comirnaty Omicron XBB.1.5 Children 5-11 years COVID-19 mRNA Vaccine 10micrograms/0.3ml dose dispersion for injection multidose vials (Pfizer Ltd)
  • Comirnaty Omicron XBB.1.5 Children 6 months – 4 years COVID-19 mRNA Vaccine 3micrograms/0.2ml dose concentrate for dispersion for injection multidose vials (Pfizer Ltd)

Release Notes

Type: Enhancement

Title: Comirnaty children COVID vaccine update

Explanation:

• Rename Comirnaty XBB 1.5 Children 5-11years to Comirnaty Omicron XBB.1.5 Children 5-11 years
• Rename Comirnaty XBB 1.5 Children 6 months -4 years to Comirnaty Omicron XBB.1.5 Children 6 months – 4 years
• Amendment of the minimum interval between booster doses from “N/A” to “91 days” for both the Comirnaty Children 5-11 years vaccine and Comirnaty Omicron XBB.1.5 Children 5-11 years vaccine.

Type: Enhancement

Title: Eligibility Screen Usability

Explanation:

• The eligibility screen has been improved based on user feedback to make the selection of an eligibility criteria clearer.

Release Notes

Type: Enhancement

Title: Decommissioned COVID vaccines for Spring campaign

Explanation:

• COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi Pasteur)  

• COVID-19 Vaccine Spikevax Original/Omicron BA.4/BA.5 dispersion for injection 0.1mg/ml multidose vials (Moderna, Inc)

• Comirnaty Children 6 months – 4 years COVID-19 mRNA Vaccine 3micrograms/0.2ml dose concentrate for dispersion for injection multidose vials (Pfizer Ltd)  

• Comirnaty Children 5-11 years COVID-19 mRNA Vaccine 10micrograms/0.2ml dose concentrate for dispersion for injection multidose vials (Pfizer Ltd)  

Type: Enhancement

Title: Usability improvement to starting encounters

Explanation:

• Changing the start encounter option from drop down selection to radio selection of Covid and Flu encounters.

Type: Enhancement

Title: Ethnicity Question

Explanation:

• Removal of ethnicity question when recording encounters as this is no longer required for POC capture.

Release Notes

Type: New Feature

Title: User Management

Explanation:

• This exciting new feature allows users with the clerical role to add new users and manage existing users in their organisations. This includes the ability to remove users and reset login credentials for organisation users.

Type: Enhancement

Title: Reporting

Explanation:

• Expansion of report suite to now include activity by site and by vaccinator.

Release Notes

Type: Enhancement

Title: Bug fixes and performance enhancement

Explanation:

• Number of bug fixes for reporting
• Code refactor to improve performance

Release Notes

NHS-RT-16.0.0

Type: Enhancement

Title: Combined permissions on assigned roles

Explanation:

• A user both clerical and clinical roles can now access all the functionality associated with their roles without the need to switch between roles on the login screen. 

Type: Enhancement

Title: People Management 

Explanation:

• Added validation to prevent duplicates of persons involved in the vaccination process added in People management
• Visual alert added where a duplicate has been identified where adding a new person 

Type: Enhancement

Title: Customer Support tool

Explanation:

• Improvements made to the user and organisation management tools available for our customer support team to allow better support and a more efficient service to our new and existing customers

Release Version

NHS-RT-17.0.0

Type: Enhancement

Title: Backend improvements

Explanation:

•  Optimisation of backend code and auditing improvements

Type:  Enhancement

Title: Update to Flu vaccination for the Autumn Winter Campaign 2024

Explanation:

• Addition of Quadrivalent influenza vaccine (split virion, inactivated) High-Dose suspension for injection 0.7ml pre-filled syringes (Sanofi)
• Addition of Influenza Tetra MYL vaccine suspension for injection 0.5ml pre-filled syringes (Viatris UK Healthcare Ltd)
• Addition of Fluenz Trivalent vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK Ltd)

Type: Enhancement

Title: Privacy statement and User guides update

Explanation:

• Update the navigation from the application to latest privacy statement
• Update to training navigation to Training & Onboarding — Telstra Health UK